We recently published 10 Stocks With Eye-Popping Double-Digit Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

More than a third of Hims & Hers public float — over 65 million shares, or about 33.5% — are being sold short, according to data from Benzinga Pro . This level of short interest is well above average ...

Hims & Hers Health ( ($HIMS) ) has risen by 21.11%. Read on to learn why. Hims & Hers Health has experienced a notable 21.11% ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...